Current Headlines

  1. XtalPi AI Drug Discovery Collaboration Reaches Milestone As PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals 9/9/2025

    XtalPi Inc. (Stock Code: 2228.HK) has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. (TWO:4162), has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors.

  2. insitro Partners With Lilly To Build First-In-Kind Machine Learning Models To Advance Small Molecule Drug Discovery 9/9/2025

    insitro, a pioneer in machine learning for drug discovery and development, today announced a new collaboration with Eli Lilly and Company (Lilly) to develop advanced machine learning models that can accurately predict key pharmacological properties of small molecules, including their behavior in vivo.

  3. Lunai Bioworks Inc. Unveils Transformer Platform To Secure Generative AI And Accelerate Drug Discovery 9/9/2025

    Lunai Bioworks Inc., an AI-powered drug discovery and biodefense company, today announced the launch of a transformer-based platform that embeds biological risk intelligence directly into large language model (LLM) pipelines.

  4. Teva's Emrusolmin Granted U.S. FDA Fast Track Designation For Treatment Of Multiple System Atrophy 9/9/2025

    Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for Teva’s investigational therapy emrusolmin (TEV-56286) for the treatment of Multiple System Atrophy (MSA).

  5. New UMaine Research Could Help Lower Prescription Drug Costs 9/8/2025

    One of the main factors driving prices in pharmaceuticals, such as cholesterol-lowering drugs and antibiotics, is the cost of production and materials.

  6. Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development 9/4/2025

    Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical innovator, today announced that it is leveraging Lantern Pharma's breakthrough PredictBBB.ai™ platform, a next-generation artificial intelligence (AI) tool with 94% accuracy in predicting blood-brain barrier permeability.

  7. Karmanos Researcher Co-Discovered Compound, Led To First FDA-Approved Therapy For Rare Brain Cancer 9/4/2025

    For Gen Sheng Wu, Ph.D., a member of the Molecular Therapeutics Research Program at the Barbara Ann Karmanos Cancer Institute and professor in the Department of Oncology and Pathology at Wayne State University School of Medicine, witnessing the research he began 20 years ago lead to a newly approved cancer treatment is a dream come true.

  8. Arcutis Submits Supplemental New Drug Application For ZORYVE® (Roflumilast) Cream 0.3% To Expand Indication For Treatment Of Plaque Psoriasis In Children Ages 2 to 5 9/3/2025

    Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to expand the indication of ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2.

  9. Elsevier Launches PharmaPendium AI, Designed To Support Faster And More Reliable Access To Regulatory Insights For Drug Development 9/3/2025

    Elsevier, a global information and analytics company, today launches PharmaPendium AI, a generative AI assistant for regulatory intelligence in drug development. The solution transforms how regulatory affairs professionals, preclinical and clinical researchers access and apply information from US Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulatory documents.

  10. Illumina® Protein Prep Launches To Drive Greater Proteomic Insights For Improved Drug Discovery And Development 9/3/2025

    Illumina Inc. (NASDAQ: ILMN) today announced the launch of Illumina Protein Prep, an assay introducing superior performance for next-generation sequencing (NGS) based proteomics discovery at scale.